Stephen P. Carey, the Senior Vice President and Chief Financial Officer of ANI Pharmaceuticals, Inc., has sold 2,850 shares of the company's common stock. This transaction, reported in a recent SEC filing, is significant as it reflects the ongoing management of stock holdings by corporate executives.

The sale took place on October 29, 2026, at a weighted average price of $72.87 per share. The shares were sold under a Rule 10b5-1 trading plan that Carey established on March 6, 2026. Following this transaction, Carey retains ownership of 166,143 shares of ANI Pharmaceuticals.

Background

ANI Pharmaceuticals, Inc. is a company focused on the development and commercialization of pharmaceutical preparations. The company is incorporated in Delaware and has its business address in Princeton, New Jersey. ANI Pharmaceuticals operates within the pharmaceutical industry, specifically categorized under pharmaceutical preparations.

What the Filing Says

The SEC filing indicates that the sale was executed as part of a pre-arranged trading plan, which is designed to allow executives to manage their stock sales in a systematic manner. The filing states, "The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026." This type of plan is often used to avoid any potential allegations of insider trading.

Impact

This transaction may influence investor perceptions of ANI Pharmaceuticals, particularly regarding the confidence of its executives in the company's future performance. As a significant player in the pharmaceutical preparations sector, ANI Pharmaceuticals competes with various other companies in the industry, although specific competitors were not mentioned in the filing.

What's Next

The filing does not say what happens next.